Prime Medicine has treated the first person with in-body prime editing, rewriting liver DNA to target Wilson disease. Results are due next year. In vivo editing is the real prize because it could be c

What happened: Prime Medicine treated the first person in a clinical trial using prime editing to rewrite DNA directly inside the body, targeting liver cells to correct a mutation causing Wilson disease. Why it matters: In vivo editing could be cheaper and faster than extracting and reinjecting a patient's cells, though the approach carries its own risks. The FDA is expected to decide early next year on an in vivo CRISPR–Cas9 therapy for hereditary angioedema.

First human prime editing directly alters DNA, a CRISPR milestone.

First human prime editing directly alters DNA, a CRISPR milestone. — impact context not separately stored; see What changed.